Hata Yujiro S — SEC insider filings
SEC reporting owner CIK 1649119. 24 insider filings on record with FilingPulse; latest filed 2026-10-08.
Transaction summary — filings shown
Covers all 24 filings on record, filed 2020-12-23 to 2026-10-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 16 legs across 6 filings — 451,338 shares, $18,544,997 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 41.
- Largest priced transaction: sale of 75,815 shares @ $45.15 ($3,422,835) in IDEAYA Biosciences, Inc., filed 2024-02-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | President and CEO, Director | 15 | — | 16 legs · 451,338 sh · $18,544,997 | 32 |
| ENANTA PHARMACEUTICALS INC (ENTA) | Director | 6 | — | — | 6 |
| Xencor Inc (XNCR) | Director | 3 | — | — | 3 |
Insider filings — Hata Yujiro S
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-08 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Option exercise (M): 26,338 @ $4.31 · Sale (S): 25,538 @ $37.39 · Sale (S): 800 @ $38.26 · Option exercise (M): 26,338 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Option exercise (M): 12,808 @ $19.52 · Option exercise (M): 12,808 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Option exercise (M): 56,711 @ $4.31 · Sale (S): 54,408 @ $41.60 · Sale (S): 2,303 @ $41.84 · Option exercise (M): 83,856 @ $4.31 · Sale (S): 53,592 @ $42.57 · Sale (S): 29,761 @ $43.48 · +7 more | EDGAR |
| 2024-03-08 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 480,000 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Option exercise (M): 75,815 @ $4.31 · Sale (S): 75,815 @ $45.15 · Option exercise (M): 23,557 @ $4.31 · Sale (S): 23,557 @ $45.54 · Option exercise (M): 75,815 (derivative) @ $0 · Option exercise (M): 23,557 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Option exercise (M): 628 @ $4.31 · Sale (S): 624 @ $45 · Sale (S): 4 @ $45.01 · Option exercise (M): 628 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Option exercise (M): 12,261 @ $4.31 · Sale (S): 12,261 @ $40.04 · Option exercise (M): 62,739 @ $4.31 · Sale (S): 62,739 @ $40.17 · Option exercise (M): 12,261 (derivative) @ $0 · Option exercise (M): 62,739 (derivative) @ $0 | EDGAR |
| 2023-12-19 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Option exercise (M): 75,000 @ $4.31 · Sale (S): 75,000 @ $35.03 · Option exercise (M): 75,000 (derivative) @ $0 | EDGAR |
| 2023-04-13 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Option exercise (M): 11,601 @ $4.31 · Option exercise (M): 11,601 (derivative) @ $0 | EDGAR |
| 2023-03-06 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 10,800 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | Xencor Inc (XNCR) | Grant/award (A): 21,412 (derivative) @ $0 | EDGAR |
| 2022-03-07 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2022-03-02 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 260,000 (derivative) @ $0 | EDGAR |
| 2021-08-23 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 13,144 (derivative) @ $0 | EDGAR |
| 2021-06-25 | 4 | Xencor Inc (XNCR) | Grant/award (A): 9,728 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4/A | Xencor Inc (XNCR) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2021-02-26 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2020-12-23 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Option exercise (M): 8,000 @ $4.31 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-17 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1649119 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs